Clinical Trial Update: A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating BGB-16673 versus investigator's choice in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma previously t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• BGB-16673

Snippet

Sponsor: BeOne Medicines | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Status: RECRUITING